Literature DB >> 24308341

cobas 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens.

Sandra D Isidean1, François Coutlée, Eduardo L Franco.   

Abstract

Cervical cancer screening incorporating high-risk human papillomavirus (HPV) detection has become the preferred screening strategy in some countries and is increasingly more widespread in other countries with organized or opportunistic screening programs. Given knowledge that high-risk HPV genotypes differ in their oncogenic potential, commercial HPV assays with genotyping capabilities have been developed and have garnered attention in the recent literature. The cobas 4800 HPV Test is a qualitative multiplex assay that provides specific genotyping information for HPV types 16 and 18, while concurrently detecting 12 other high-risk HPV genotypes as a pooled result. It is currently the only clinically validated, US FDA-approved assay with this capability. Since HPV types 16 and 18 have been designated as conferring the greatest risk for cervical disease, their detection may prove useful in guiding patient management.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24308341     DOI: 10.1586/14737159.2014.865521

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  8 in total

1.  Association of low expression of E-cadherin and β-catenin with the progression of early stage human squamous cervical cancer.

Authors:  Jing Jiang; Xinling Li; Xiangmei Yin; Jieying Zhang; Bin Shi
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

2.  The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test.

Authors:  Mark Schiffman; Sean Boyle; Tina Raine-Bennett; Hormuzd A Katki; Julia C Gage; Nicolas Wentzensen; Janet R Kornegay; Raymond Apple; Carrie Aldrich; Henry A Erlich; Thanh Tam; Brian Befano; Robert D Burk; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-18       Impact factor: 4.254

3.  Verification of the association of the cycle threshold (Ct) values from HPV testing on Cobas4800 with the histologic grades of cervical lesions using data from two population-based cervical cancer screening trials.

Authors:  Yi Zhang; Hui Du; Aimin Xiao; Wei Zhang; Chun Wang; Xia Huang; Xinfeng Qu; Jianliu Wang; Ruifang Wu
Journal:  Infect Agent Cancer       Date:  2022-06-11       Impact factor: 3.698

Review 4.  Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.

Authors:  Mariam El-Zein; Lyndsay Richardson; Eduardo L Franco
Journal:  J Clin Virol       Date:  2015-11-18       Impact factor: 3.168

5.  Sputasol (Dithiothreitol 0.54%) Improves the Detection of Human Papillomaviruses Using the Cobas 4800 System.

Authors:  Qing Yong Wang; He Rui Zhang; Yu Gao; Rong Hai Li; Xiao Hong Shang
Journal:  Ann Lab Med       Date:  2017-09       Impact factor: 3.464

6.  An Evaluation of the Cobas4800 HPV Test on Cervico-Vaginal Specimens in Liquid versus Solid Transport Media.

Authors:  Hongxue Luo; Hui Du; Kathryn Maurer; Jerome L Belinson; Guixiang Wang; Zhihong Liu; Lijie Zhang; Yanqiu Zhou; Chun Wang; Jinlong Tang; Xinfeng Qu; Ruifang Wu
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

7.  Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing.

Authors:  Farzane Jamdar; Farah Farzaneh; Fariba Navidpour; Sarang Younesi; Payam Balvayeh; Maryamsadat Hosseini; Robabeh Ghodssi-Ghasemabadi
Journal:  Infect Agent Cancer       Date:  2018-01-25       Impact factor: 2.965

8.  High risk genotype distribution of human papillomavirus (HPV) according to age groups in Iranian asymptomatic men.

Authors:  Mehrdad Davarmanesh; Seyed Mohammad Jazayeri; Mehrouz Dezfulian; Mohammad Javad Gharavi
Journal:  Infect Agent Cancer       Date:  2020-05-06       Impact factor: 2.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.